Microneedle assisted drug delivery of liposome loaded with selegiline hydrochloride for effective management of Parkinson’s disease intervention

Microneedles assisted transdermal delivery of cationic liposomes loaded with selegiline hydrochloride is an innovative approach to treat the symptoms of Parkinson’s disease. Previously optimized liposomes of selegiline hydrochloride (SH-LP3) were incorporated within the microneedle array by solvent casting method. The microneedle patch (SH-LP3-MNP) had uniform thickness with an optimum moisture percentage that maintains the mechanical strength of the needle tips. Through an FT-IR study, selegiline and PVA were found to be compatible, showing their prominent functional group. The shape, size, and needle tips of the microneedle were confirmed via SEM analysis. Ex vivo permeability study resembles higher permeation of liposomes through SH-LP3-MNP formulation when compared with SH-MNP. This study also resulted in lower drug retention within the skin membrane. Pharmacokinetic evaluation in Wistar rats indicated that the liposome-loaded microneedles released selegiline in a sustained manner and maintained drug levels in the bloodstream for a longer period, which was reflected by a higher AUC value. The sensory motor coordination of rats improved in microneedle assisted delivery as shown in in vivo antiparkinson disease study. Biochemical tests supported these findings by showing increased antioxidant enzyme activity, reduced lipid peroxidation, and a noticeable rise in dopamine levels in brain tissue. A histopathological study showed improved neuronal regeneration for the SH-LP3-MNP formulation. Through these findings, it was reported that the SH-LP3-MNP formulation is a promising approach for delivering liposomes loaded with selegiline through the skin for the treatment of Parkinson’s disease symptoms.